MAGLIN1

MAGL-IN-1 is a selective and potent monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 80 nM.

MAGL-IN-18 (compound 118) serves as a highly potent inhibitor of Monoacylglycerol lipase (MAGL), demonstrating an IC 50 value of 0.03nM.

MAGL-IN-19 (compound 7o) is a highly effective and selective inhibitor of MAGL.

MAGL-IN-13 (compound(3R,4S)-5v) is a selective, irreversible MAGL inhibitor with IC50 values of 0.026 nM for mMAGL, 0.021 nM for hMAGL, and 0.24 nM for rMAGL. Additionally, MAGL-IN-13 is capable of crossing the blood-brain barrier.

MAGL-IN-16 (compound 27) is an orally active, selective, and reversible MAGL inhibitor with an IC50 value of 10.3 nM. It increases 2-AG levels in vivo and exhibits antidepressant effects in mouse models of chronic restraint stress-induced depression.

FAAH/MAGL-IN-1, also known as compound SIH 3, is a highly effective inhibitor of FAAH (fatty acid amide hydrolase) and MAGL (monoacylglycerol lipase). It exhibits IC50 values of 31 nM and 29 nM against FAAH and MAGL, respectively. This compound shows promising potential for advancing research in the field of neuropathic pain [1].

MAGL-IN-11 (compound 29) is a selective, reversible inhibitor of monoacylglycerol lipase (MAGL) with potential applications in inflammation, cancer, and antioxidant research [1].

MAGL-IN-10, a reversible monoacylglycerol lipase (MAGL) inhibitor, exhibits favorable ADME properties and low in vivo toxicity. It is applicable in the study of cancer, neurological disorders, and inflammatory pathologies [1].

MAGL-IN-14 (compound 2) serves as a potent MAGL inhibitor, exhibiting IC50 values of 0.00289 μM in HEK293 cells and 0.002 μM in PC3 cells [1].

MAGL-IN-15 (Compound 6), a MAGL inhibitor, holds potential for research into diseases and disorders associated with the regulation of endocannabinoid system signaling activities [1].